Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LifeMD, Inc.LFMD · Entity 6521 | Director | August 11, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LifeMD, Inc.
Report date August 11, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 142,050 |
Reported balance
After 2026-08-11 transaction · row 1
1 source rowRow 1 · 2026-08-11 · Grant · Acquired 35,000 · Balance 142,050 F1: The grant of restricted shares vests on June 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant of restricted shares vests on June 1, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2026 Filed Aug 18, 2026 22:12 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-26-001129 · form4.xml · nonDerivative · entry 1 LAROVERE JOAN · CIK 0001961270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,050 F1 · price: The grant of restricted shares vests on June 1, 2027. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 22:03 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 22,365 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001048 · form4.xml · nonDerivative · entry 1 LAROVERE JOAN · CIK 0001961270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,050 F1 · price: The grant of restricted shares vests on June 1, 2026. Read SEC document |
| December 20, 2024 Filed Dec 26, 2024 15:27 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 9,685 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000912282-24-000913 · form4.xml · nonDerivative · entry 1 LAROVERE JOAN · CIK 0001961270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,685 F1 · price: Pursuant to the Company's 2020 Equity and Incentive Plan, as amended, the reporting person received a grant of 9,685 restricted shares, vesting immediately. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 16:45 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001362118-23-000013 · primary_doc.xml · derivative · entry 2 LAROVERE JOAN · CIK 0001961270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2028-02-09 F2 · derivative.exercise_date: The option vests on the two year anniversary of the date of grant. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 16:45 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001362118-23-000013 · primary_doc.xml · nonDerivative · entry 1 LAROVERE JOAN · CIK 0001961270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · price: Pursuant to the Company's 2020 Equity and Incentive Plan, as amended, the reporting person received a grant of 75,000 restricted shares, with 37,500 vesting immediately and 37,500 shares vesting on the two year anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.